Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 3/20 | 0.36 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | MMP8 | P22894 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3449171 | 0.84 | CHRM1 (0.33) | CHRM1CHRM4CHRM5ALDH1A1LMNA | |
| SCHEMBL6015137 | 0.75 | KMT2A (0.46) | CHRM1ALDH1A1KMT2ACYP3A4 | |
| SCHEMBL3452052 | 0.69 | — | — | |
| SCHEMBL3448878 | 0.69 | — | — | |
| SCHEMBL3450523 | 0.67 | FPR2 (0.50) | CHRM1ALDH1A1CYP3A4 | |
| SCHEMBL3451771 | 0.66 | TP53 (0.37) | KMT2A | |
| SCHEMBL3449162 | 0.65 | — | — | |
| SCHEMBL3447797 | 0.65 | ALDH1A1 (0.41) | CHRM1CHRM4CHRM5ALDH1A1LMNA | |
| SCHEMBL3449478 | 0.65 | EPHX2 (0.33) | ALDH1A1LMNAKMT2ACYP2C9CYP2C19 | |
| SCHEMBL3448869 | 0.65 | HRH2 (0.33) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7820673-B2 | Urea derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-10-26 | — | — | US | disclosed |
| US-20070093501-A1 | Urea derivative, process for producing the same, and use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093501-A1 | Urea derivative, process for producing the same, and use | F2, URB2, F12 | CHRM1 898/4885CHRM4 3021/4885CHRM5 2348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.